Case Info
Dupixent May Increase the Risk for Certain Lymphoma Cancers
Dupixent (dupilumab) is an injectable biologic medication used to treat certain types of inflammatory diseases. It works by treating the underlying cause of inflammation and is commonly prescribed for people with atopic dermatitis, eczema, asthma, chronic sinusitis, and eosinophilic esophagitis.
Recent studies have shown that Dupixent use may increase the risk of certain types of cancers known as Cutaneous T-cell Lymphomas (CTCL) ), including its subtypes Mycosis fungoides and Sezary syndrome, by as much as 300% or more in people who used the medication. People who used Dupixent and were later diagnosed with CTCL may be eligible for compensation
Dupixent Cutaneous T-cell Lymphoma Cancer Risk
As part of the immune system, skin plays a major role in the lymphatic system. Certain cancers of the lymph system are known as Lymphomas.
Cutaneous T-cell Lymphoma is a type of cancer that originates in the skin. It is one of the non-Hodgkins Lymphoma group of cancers that affects a certain type of white blood cell known as T-cells.
CTCL may include subtypes of Cutaneous T-cell Lymphoma including Sezary Syndrome, Mycosis Fungoides, and other T-cell Lymphoma subtypes.
Symptoms of CTCL may include:
- Itching
- Red, scaly, or thickened patches of skin
- Peeling skin
- Discolored skin
- Raised bumps or nodules
- Skin sores or ulcers
- Hair loss
- Enlarged lymph nodes
Recently published studies showed that Dupixent may increase the risk of development of CTCL by 300% or more. In some cases, Dupixent may have hidden undetected CTCL when it was used to treat conditions with similar symptoms to cancer or may have worsened existing conditions. Drug manufacturers may have known about the risks of their medications and failed to warn patients and the medical community.
People or loved ones of those who took Dupixent for conditions such as eczema, atopic dermatitis, or other conditions and later developed Cutaneous T-cell Lymphoma (CTCL), Sezary Syndrome, or Mycosis Fungoides may be eligible for compensation.